Cargando…

Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy

SIMPLE SUMMARY: One promising avenue for the treatment of colorectal cancer is the reinvigoration of pre-existing anti-tumor T-cell responses by overcoming inhibitions that arise from the T-cell expression of immune checkpoints. This study aims to perform an in-depth assessment of human colorectal c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ducoin, Kathleen, Bilonda-Mutala, Linda, Deleine, Cécile, Oger, Romain, Duchalais, Emilie, Jouand, Nicolas, Bossard, Céline, Jarry, Anne, Gervois-Segain, Nadine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454990/ https://www.ncbi.nlm.nih.gov/pubmed/36077799 http://dx.doi.org/10.3390/cancers14174261

Ejemplares similares

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer
por: Ducoin, Kathleen, et al.
Publicado: (2022)

The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer
por: Mutala, Linda Bilonda, et al.
Publicado: (2021)

The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status
por: Ott, Eva, et al.
Publicado: (2019)

Editorial: Crosstalk between innate and adaptive immunity in colorectal cancer: Implications for immunotherapy
por: Jarry, Anne, et al.
Publicado: (2023)

HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition
por: Jouand, Nicolas, et al.
Publicado: (2018)

A novel and efficient approach to high-throughput production of HLA-E/peptide monomer for T-cell epitope screening
por: Vaurs, Juliette, et al.
Publicado: (2021)

Examination of the TIGIT-CD226-CD112-CD155 Immune Checkpoint Network during a Healthy Pregnancy
por: Meggyes, Matyas, et al.
Publicado: (2022)

Prognostic value of CD155/TIGIT expression in patients with colorectal cancer
por: Murakami, Daisuke, et al.
Publicado: (2022)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway
por: Ma, Bin, et al.
Publicado: (2019)

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
por: Wang, Daijun, et al.
Publicado: (2022)

The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

TIGIT is a key inhibitory checkpoint receptor in lymphoma
por: Godfrey, James, et al.
Publicado: (2023)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer
por: Barret, Jean-Marc, et al.
Publicado: (2021)

Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma
por: Duan, Xiangguo, et al.
Publicado: (2019)

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis
por: Ozmadenci, Duygu, et al.
Publicado: (2022)

CD40L confers helper functions to human intra-melanoma class-I-restricted CD4(+)CD8(+) double positive T cells
por: Parrot, Tiphaine, et al.
Publicado: (2016)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia
por: Seiffert, Martina
Publicado: (2023)

Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia
por: Szereday, Laszlo, et al.
Publicado: (2021)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT
por: Matsuo, Tomohei, et al.
Publicado: (2022)

NEIM-01 IMMUNOSUPPRESSION IN THE GLIOMA MICROENVIRONMENT: USING PET IMAGING TO HIGHLIGHT THE PRESENCE OF TIGIT
por: Frederico, Stephen, et al.
Publicado: (2023)

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020)

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
por: Ge, Zhouhong, et al.
Publicado: (2021)

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
por: Zeven, Katty, et al.
Publicado: (2023)

High-Density of FcγRIIIA(+) (CD16(+)) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis
por: Denis Musquer, Marie, et al.
Publicado: (2021)

Blocking TIGIT/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer
por: Liu, Lu, et al.
Publicado: (2022)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis
por: Deng, Chuiwen, et al.
Publicado: (2020)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Data highlighting miR-155 and GAPDH correlation
por: Khanna, Madhu, et al.
Publicado: (2019)

HLA-E-Restricted Cross-Recognition of Allogeneic Endothelial Cells by CMV-Associated CD8 T Cells: A Potential Risk Factor following Transplantation
por: Allard, Mathilde, et al.
Publicado: (2012)

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f15uvu26kle59ug9p6gakdaoc3